Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1

Interventions

Gemcitabine 27Taxes 9Capecitabine 8Albumin-Bound Paclitaxel 6pembrolizumab 5Radiosurgery 5Oxaliplatin 5Bevacizumab 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Specimen Handling 4Secretin 4Fluorouracil 4Drug Therapy 4Ascorbic Acid 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Cyclophosphamide 3Cisplatin 3Biopsy 3palbociclib 2methylnaltrexone 2folfirinox 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Pancreatic Neoplasms × PEGPH20 × Clear all
NCT04058964 2020-03-13

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡